Lescarden Inc logo

LCAR - Lescarden Inc Share Price

$0.002 0.0  0.0%

Last Trade - 18/06/20

Micro Cap
Market Cap £122k
Enterprise Value £268k
Revenue £340k
Position in Universe th / 6344
Unlock LCAR Revenue
Relative Strength (%)
1m +22.5%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -63.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st May 2011 2012 2013 2014 2015 2016 2017E 2018E CAGR / Avg
0.56 0.42 0.40 0.40 0.25 0.12 -26.5%
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 28 February 2017, Lescarden Inc. revenues increased from $112K to $417K. Net income totaled $26K vs. loss of $78K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Rent and office expense decrease of 26% to $9K (expense), Salaries decrease of 5% to $46K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


LCAR Revenue Unlock LCAR Revenue

Net Income

LCAR Net Income Unlock LCAR Revenue

Normalised EPS

LCAR Normalised EPS Unlock LCAR Revenue

PE Ratio Range

LCAR PE Ratio Range Unlock LCAR Revenue

Dividend Yield Range

LCAR Dividend Yield Range Unlock LCAR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
LCAR EPS Forecasts Unlock LCAR Revenue
Profile Summary

Lescarden Inc. is engaged in the research, testing and development of medications for the control and cure of various diseases, and the licensing of its technologies for commercialization by other companies. The Company's product line is led by Catrix Wound Dressing, a powder derived from bovine cartilage for the management of chronic lesions and burns, and helpful when applied to non-healing wounds, such as decubitus ulcers, venous stasis ulcers and diabetic ulcers. It also offers Catrix-based skin care products targeting the plastic surgery, dermatology and medical spa markets. It sells two nutritional supplements, including Bio-Cartilage and Poly-NAG, a glucosamine polymer. It has also developed a 5% Catrix Rejuvenation Cream and a 5% Catrix Lip Balm. Derived from specially processed crustacean shells, Poly-NAG is a polymeric form of glucosamine (Poly-N-Acetyl-D-Glucosamine) that is marketed by the Company in the anti-arthritic market as a treatment for osteoarthritis.

Last Annual May 31st, 2016
Last Interim February 28th, 2017
Incorporated September 19, 1960
Public Since October 27, 1993
No. of Shareholders: n/a
No. of Employees: 1
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange OTC Markets Group
Shares in Issue 63,622,316
Free Float (0.0%)
Eligible for
LCAR Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for LCAR
Upcoming Events for LCAR
Frequently Asked Questions for Lescarden Inc
What is the Lescarden Inc share price?

As of 18/06/20, shares in Lescarden Inc are trading at $0.002, giving the company a market capitalisation of £122k. This share price information is delayed by 15 minutes.

How has the Lescarden Inc share price performed this year?

Shares in Lescarden Inc are currently trading at $0.002 and the price has moved by -63.08% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Lescarden Inc price has moved by -62.97% over the past year.

What are the analyst and broker recommendations for Lescarden Inc?

There are no analysts currently covering Lescarden Inc.

When will Lescarden Inc next release its financial results?

Lescarden Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2018-02-28
What is the Lescarden Inc dividend yield?

Lescarden Inc does not currently pay a dividend.

Does Lescarden Inc pay a dividend?

Lescarden Inc does not currently pay a dividend.

When does Lescarden Inc next pay dividends?

Lescarden Inc does not currently pay a dividend.

How do I buy Lescarden Inc shares?

To buy shares in Lescarden Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Lescarden Inc?

Shares in Lescarden Inc are currently trading at $0.002, giving the company a market capitalisation of £122k.

Where are Lescarden Inc shares listed? Where are Lescarden Inc shares listed?

Here are the trading details for Lescarden Inc:

Country of listing: United States
Exchange: OTC
Ticker Symbol: LCAR
What kind of share is Lescarden Inc?

We were not able to load our ranking data for Lescarden Inc

Is there a Lescarden Inc share price forecast 2020?

We were not able to load any forecast data for Lescarden Inc.

How can I tell whether the Lescarden Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lescarden Inc. Over the past six months, the relative strength of its shares against the market has been 60.82%. At the current price of $0.002, shares in Lescarden Inc are trading at -87.5% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Lescarden Inc PE Ratio?

We were not able to find PE ratio data for Lescarden Inc.

Who are the key directors of Lescarden Inc?

Lescarden Inc's management team is headed by:

William Luther - CEO
Russell Wiese - DRC
Xavier Balaguer - DRC
Charles Maxwell - DRC
Who are the major shareholders of Lescarden Inc?

Here are the top five shareholders of Lescarden Inc based on the size of their shareholding:

Glenmede Investment Management LP Investment Advisor/Hedge Fund
Percentage owned: 0.14% (90.0k shares)
Bryn Mawr Trust Company Bank and Trust
Percentage owned: 0.05% (30.0k shares)
Similar to LCAR
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.